{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:22:45Z","timestamp":1785522165031,"version":"3.56.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s12325-026-03552-0","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T08:16:16Z","timestamp":1779783376000},"page":"3351-3368","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Disease-Modifying Therapies in Spinal Muscular Atrophy: Neurodevelopmental and Behavioral Outcomes in the Treatment Era"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5677-4222","authenticated-orcid":false,"given":"Kentaro","family":"Okamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"issue":"1","key":"3552_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre S, B\u00fcrglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80(1):155\u201365. https:\/\/doi.org\/10.1016\/0092-8674(95)90460-3.","journal-title":"Cell"},{"issue":"8","key":"3552_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100725","volume":"3","author":"AAL Motyl","year":"2022","unstructured":"Motyl AAL, Gillingwater TH. Timing is everything: clinical evidence supports pre-symptomatic treatment for spinal muscular atrophy. Cell Rep Med. 2022;3(8):100725. https:\/\/doi.org\/10.1016\/j.xcrm.2022.100725.","journal-title":"Cell Rep Med"},{"issue":"2","key":"3552_CR3","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/s0960-8966(01)00274-7","volume":"12","author":"A von Gontard","year":"2002","unstructured":"von Gontard A, Zerres K, Backes M, et al. Intelligence and cognitive function in children and adolescents with spinal muscular atrophy. Neuromuscul Disord. 2002;12(2):130\u20136. https:\/\/doi.org\/10.1016\/s0960-8966(01)00274-7.","journal-title":"Neuromuscul Disord"},{"issue":"13","key":"3552_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e33677","volume":"10","author":"S Akodad","year":"2024","unstructured":"Akodad S, De Smedt D, Baijot S, Stevens H, Deconinck N. Cognition and communication in patients with spinal muscular atrophy: a systematic review. Heliyon. 2024;10(13):e33677. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e33677.","journal-title":"Heliyon"},{"issue":"5","key":"3552_CR5","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/dmcn.14798","volume":"63","author":"R Masson","year":"2021","unstructured":"Masson R, Brusa C, Scoto M, Baranello G. Brain, cognition, and language development in spinal muscular atrophy type 1: a scoping review. Dev Med Child Neurol. 2021;63(5):527\u201336. https:\/\/doi.org\/10.1111\/dmcn.14798.","journal-title":"Dev Med Child Neurol"},{"issue":"3","key":"3552_CR6","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1207\/S15326942DN2103_4","volume":"21","author":"J Rivi\u00e8re","year":"2002","unstructured":"Rivi\u00e8re J, L\u00e9cuyer R. Spatial cognition in young children with spinal muscular atrophy. Dev Neuropsychol. 2002;21(3):273\u201383. https:\/\/doi.org\/10.1207\/S15326942DN2103_4.","journal-title":"Dev Neuropsychol"},{"issue":"2","key":"3552_CR7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ejpn.2005.02.001","volume":"9","author":"C B\u00e9nony","year":"2005","unstructured":"B\u00e9nony C, B\u00e9nony H. Precocity of the acquisition of language and type II spinal muscular atrophy in 3-4-year-old children: a study of 12 cases. Eur J Paediatr Neurol. 2005;9(2):71\u20136. https:\/\/doi.org\/10.1016\/j.ejpn.2005.02.001.","journal-title":"Eur J Paediatr Neurol"},{"issue":"6","key":"3552_CR8","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.ejpn.2005.08.002","volume":"9","author":"JS Sieratzki","year":"2005","unstructured":"Sieratzki JS, Woll B. Moving ahead in language: observations on a report of precocious language development in 3-4 year old children with spinal muscular atrophy type II. Eur J Paediatr Neurol. 2005;9(6):433\u20134. https:\/\/doi.org\/10.1016\/j.ejpn.2005.08.002.","journal-title":"Eur J Paediatr Neurol"},{"issue":"7-8","key":"3552_CR9","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/s0960-8966(02)00048-2","volume":"12","author":"JS Sieratzki","year":"2002","unstructured":"Sieratzki JS, Woll B. Cognitive function in children with spinal muscular atrophy. Neuromuscul Disord. 2002;12(7\u20138):693\u20134. https:\/\/doi.org\/10.1016\/s0960-8966(02)00048-2. (author reply 694).","journal-title":"Neuromuscul Disord"},{"issue":"5","key":"3552_CR10","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.nmd.2017.01.017","volume":"27","author":"GJ Polido","year":"2017","unstructured":"Polido GJ, Barbosa AF, Morimoto CH, et al. Matching pairs difficulty in children with spinal muscular atrophy type I. Neuromuscul Disord. 2017;27(5):419\u201327. https:\/\/doi.org\/10.1016\/j.nmd.2017.01.017.","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"3552_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01661-9","volume":"16","author":"L Mix","year":"2021","unstructured":"Mix L, Schreiber-Katz O, Wurster CD, et al. Executive function is inversely correlated with physical function: the cognitive profile of adult spinal muscular atrophy (SMA). Orphanet J Rare Dis. 2021;16(1):10. https:\/\/doi.org\/10.1186\/s13023-020-01661-9.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"3552_CR12","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1590\/1980-57642018dn13-040011","volume":"13","author":"GJ Polido","year":"2019","unstructured":"Polido GJ, de Miranda MMV, Carvas N, et al. Cognitive performance of children with spinal muscular atrophy: a systematic review. Dement Neuropsychol. 2019;13(4):436\u201343. https:\/\/doi.org\/10.1590\/1980-57642018dn13-040011.","journal-title":"Dement Neuropsychol"},{"key":"3552_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1226043","volume":"14","author":"Y Hu","year":"2023","unstructured":"Hu Y, Wei L, Li A, et al. Cognitive impairment in Chinese adult patients with type III spinal muscular atrophy without disease-modifying treatment. Front Neurol. 2023;14:1226043. https:\/\/doi.org\/10.3389\/fneur.2023.1226043.","journal-title":"Front Neurol"},{"issue":"14","key":"3552_CR14","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1002\/j.1460-2075.1996.tb00725.x","volume":"15","author":"Q Liu","year":"1996","unstructured":"Liu Q, Dreyfuss G. A novel nuclear structure containing the survival of motor neurons protein. EMBO J. 1996;15(14):3555\u201365.","journal-title":"EMBO J"},{"issue":"6","key":"3552_CR15","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/s0092-8674(00)80367-0","volume":"90","author":"Q Liu","year":"1997","unstructured":"Liu Q, Fischer U, Wang F, Dreyfuss G. The spinal muscular atrophy disease gene product, SMN, and its associated protein SIP1 are in a complex with spliceosomal snRNP proteins. Cell. 1997;90(6):1013\u201321. https:\/\/doi.org\/10.1016\/s0092-8674(00)80367-0.","journal-title":"Cell"},{"issue":"1","key":"3552_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/83014","volume":"8","author":"P Selenko","year":"2001","unstructured":"Selenko P, Sprangers R, Stier G, B\u00fchler D, Fischer U, Sattler M. SMN tudor domain structure and its interaction with the Sm proteins. Nat Struct Mol Biol. 2001;8(1):27\u201331. https:\/\/doi.org\/10.1038\/83014.","journal-title":"Nat Struct Mol Biol"},{"issue":"9","key":"3552_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0000921","volume":"2","author":"F Gabanella","year":"2007","unstructured":"Gabanella F, Butchbach MER, Saieva L, Carissimi C, Burghes AHM, Pellizzoni L. Ribonucleoprotein assembly defects correlate with spinal muscular atrophy severity and preferentially affect a subset of spliceosomal snRNPs. PLoS ONE. 2007;2(9):e921. https:\/\/doi.org\/10.1371\/journal.pone.0000921.","journal-title":"PLoS ONE"},{"issue":"3","key":"3552_CR18","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/ng0797-265","volume":"16","author":"S Lefebvre","year":"1997","unstructured":"Lefebvre S, Burlet P, Liu Q, et al. Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet. 1997;16(3):265\u20139. https:\/\/doi.org\/10.1038\/ng0797-265.","journal-title":"Nat Genet"},{"issue":"6","key":"3552_CR19","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/s0092-8674(00)80368-2","volume":"90","author":"U Fischer","year":"1997","unstructured":"Fischer U, Liu Q, Dreyfuss G. The SMN-SIP1 complex has an essential role in spliceosomal snRNP biogenesis. Cell. 1997;90(6):1023\u20139. https:\/\/doi.org\/10.1016\/s0092-8674(00)80368-2.","journal-title":"Cell"},{"issue":"4","key":"3552_CR20","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/sj.embor.7400941","volume":"8","author":"L Pellizzoni","year":"2007","unstructured":"Pellizzoni L. Chaperoning ribonucleoprotein biogenesis in health and disease. EMBO Rep. 2007;8(4):340\u20135. https:\/\/doi.org\/10.1038\/sj.embor.7400941.","journal-title":"EMBO Rep"},{"issue":"13","key":"3552_CR21","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1093\/hmg\/8.13.2351","volume":"8","author":"D B\u00fchler","year":"1999","unstructured":"B\u00fchler D, Raker V, L\u00fchrmann R, Fischer U. Essential role for the tudor domain of SMN in spliceosomal U snRNP assembly: implications for spinal muscular atrophy. Hum Mol Genet. 1999;8(13):2351\u20137. https:\/\/doi.org\/10.1093\/hmg\/8.13.2351.","journal-title":"Hum Mol Genet"},{"issue":"5","key":"3552_CR22","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.celrep.2013.11.012","volume":"5","author":"S Tisdale","year":"2013","unstructured":"Tisdale S, Lotti F, Saieva L, et al. SMN is essential for the biogenesis of U7 small nuclear ribonucleoprotein and 3\u2019-end formation of histone mRNAs. Cell Rep. 2013;5(5):1187\u201395. https:\/\/doi.org\/10.1016\/j.celrep.2013.11.012.","journal-title":"Cell Rep"},{"issue":"7","key":"3552_CR23","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1016\/j.celrep.2017.01.059","volume":"18","author":"PG Donlin-Asp","year":"2017","unstructured":"Donlin-Asp PG, Fallini C, Campos J, et al. The Survival of Motor Neuron Protein acts as a molecular chaperone for mRNP assembly. Cell Rep. 2017;18(7):1660\u201373. https:\/\/doi.org\/10.1016\/j.celrep.2017.01.059.","journal-title":"Cell Rep"},{"issue":"2","key":"3552_CR24","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S0002-9440(10)65578-2","volume":"153","author":"EF Tizzano","year":"1998","unstructured":"Tizzano EF, Cabot C, Baiget M. Cell-specific Survival Motor Neuron gene expression during human development of the central nervous system: implications for the pathogenesis of Spinal Muscular Atrophy. Am J Pathol. 1998;153(2):355\u201361. https:\/\/doi.org\/10.1016\/S0002-9440(10)65578-2.","journal-title":"Am J Pathol"},{"issue":"12","key":"3552_CR25","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1093\/hmg\/7.12.1927","volume":"7","author":"P Burlet","year":"1998","unstructured":"Burlet P, Huber C, Bertrandy S, et al. The distribution of SMN protein complex in human fetal tissues and its alteration in Spinal Muscular Atrophy. Hum Mol Genet. 1998;7(12):1927\u201333. https:\/\/doi.org\/10.1093\/hmg\/7.12.1927.","journal-title":"Hum Mol Genet"},{"issue":"3","key":"3552_CR26","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/01.jnen.0000205144.54457.a3","volume":"65","author":"A Giavazzi","year":"2006","unstructured":"Giavazzi A, Setola V, Simonati A, Battaglia G. Neuronal-specific roles of the survival motor neuron protein: evidence from survival motor neuron expression patterns in the developing human central nervous system. J Neuropathol Exp Neurol. 2006;65(3):267\u201377. https:\/\/doi.org\/10.1097\/01.jnen.0000205144.54457.a3.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"16","key":"3552_CR27","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1093\/hmg\/ddy195","volume":"27","author":"EJN Groen","year":"2018","unstructured":"Groen EJN, Perenthaler E, Courtney NL, et al. Temporal and tissue-specific variability of SMN protein levels in mouse models of Spinal Muscular Atrophy. Hum Mol Genet. 2018;27(16):2851\u201362. https:\/\/doi.org\/10.1093\/hmg\/ddy195.","journal-title":"Hum Mol Genet"},{"issue":"11","key":"3552_CR28","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1172\/JCI124120","volume":"129","author":"DM Ramos","year":"2019","unstructured":"Ramos DM, d\u2019Ydewalle C, Gabbeta V, et al. Age-dependent SMN expression in disease-relevant tissue and implications for SMA treatment. J Clin Invest. 2019;129(11):4817\u201331. https:\/\/doi.org\/10.1172\/JCI124120.","journal-title":"J Clin Invest"},{"issue":"4","key":"3552_CR29","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1083\/jcb.200304128","volume":"163","author":"W Rossoll","year":"2003","unstructured":"Rossoll W, Jablonka S, Andreassi C, et al. Smn, the Spinal Muscular Atrophy\u2013determining gene product, modulates axon growth and localization of \u03b2-actin mRNA in growth cones of motoneurons. J Cell Biol. 2003;163(4):801\u201312. https:\/\/doi.org\/10.1083\/jcb.200304128.","journal-title":"J Cell Biol"},{"issue":"1","key":"3552_CR30","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1083\/jcb.200703187","volume":"179","author":"S Jablonka","year":"2007","unstructured":"Jablonka S, Beck M, Lechner BD, Mayer C, Sendtner M. Defective Ca2+ channel clustering in axon terminals disturbs excitability in motoneurons in Spinal Muscular Atrophy. J Cell Biol. 2007;179(1):139\u201349. https:\/\/doi.org\/10.1083\/jcb.200703187.","journal-title":"J Cell Biol"},{"issue":"16","key":"3552_CR31","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1093\/hmg\/ddn156","volume":"17","author":"S Kariya","year":"2008","unstructured":"Kariya S, Park GH, Maeno-Hikichi Y, et al. Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of Spinal Muscular Atrophy. Hum Mol Genet. 2008;17(16):2552\u201369. https:\/\/doi.org\/10.1093\/hmg\/ddn156.","journal-title":"Hum Mol Genet"},{"issue":"11","key":"3552_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0015457","volume":"5","author":"KKY Ling","year":"2010","unstructured":"Ling KKY, Lin MY, Zingg B, Feng Z, Ko CP. Synaptic defects in the spinal and neuromuscular circuitry in a mouse model of spinal muscular atrophy. PLoS ONE. 2010;5(11):e15457. https:\/\/doi.org\/10.1371\/journal.pone.0015457.","journal-title":"PLoS ONE"},{"issue":"3","key":"3552_CR33","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.neuron.2010.12.032","volume":"69","author":"GZ Mentis","year":"2011","unstructured":"Mentis GZ, Blivis D, Liu W, et al. Early functional impairment of sensory-motor connectivity in a mouse model of spinal muscular atrophy. Neuron. 2011;69(3):453\u201367. https:\/\/doi.org\/10.1016\/j.neuron.2010.12.032.","journal-title":"Neuron"},{"issue":"7","key":"3552_CR34","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/nn.4561","volume":"20","author":"EV Fletcher","year":"2017","unstructured":"Fletcher EV, Simon CM, Pagiazitis JG, et al. Reduced sensory synaptic excitation impairs motor neuron function via Kv2.1 in spinal muscular atrophy. Nat Neurosci. 2017;20(7):905\u201316. https:\/\/doi.org\/10.1038\/nn.4561.","journal-title":"Nat Neurosci"},{"issue":"2","key":"3552_CR35","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.cell.2012.09.012","volume":"151","author":"F Lotti","year":"2012","unstructured":"Lotti F, Imlach WL, Saieva L, et al. An SMN-dependent U12 splicing event essential for motor circuit function. Cell. 2012;151(2):440\u201354. https:\/\/doi.org\/10.1016\/j.cell.2012.09.012.","journal-title":"Cell"},{"issue":"48","key":"3552_CR36","doi-asserted-by":"publisher","first-page":"11559","DOI":"10.1523\/JNEUROSCI.1528-17.2017","volume":"37","author":"T Hao le","year":"2017","unstructured":"Hao le T, Duy PQ, An M, et al. HuD and the Survival Motor Neuron Protein interact in motoneurons and are essential for motoneuron development, function, and mRNA regulation. J Neurosci. 2017;37(48):11559\u201371. https:\/\/doi.org\/10.1523\/JNEUROSCI.1528-17.2017.","journal-title":"J Neurosci"},{"issue":"10","key":"3552_CR37","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1016\/j.celrep.2019.11.013","volume":"29","author":"A Vukojicic","year":"2019","unstructured":"Vukojicic A, Delestr\u00e9e N, Fletcher EV, et al. The Classical Complement Pathway mediates microglia-dependent remodeling of spinal motor circuits during development and in SMA. Cell Rep. 2019;29(10):3087-3100.e7. https:\/\/doi.org\/10.1016\/j.celrep.2019.11.013.","journal-title":"Cell Rep"},{"key":"3552_CR38","doi-asserted-by":"publisher","unstructured":"Gerstner F, Wittig S, Menedo C, et al. Cerebellar pathology contributes to neurodevelopmental deficits in spinal muscular atrophy. Brain. 2025:awaf336. https:\/\/doi.org\/10.1093\/brain\/awaf336.","DOI":"10.1093\/brain\/awaf336"},{"issue":"21","key":"3552_CR39","doi-asserted-by":"publisher","first-page":"4216","DOI":"10.1093\/hmg\/ddq340","volume":"19","author":"TM Wishart","year":"2010","unstructured":"Wishart TM, Huang JPW, Murray LM, et al. SMN deficiency disrupts brain development in a mouse model of severe spinal muscular atrophy. Hum Mol Genet. 2010;19(21):4216\u201328. https:\/\/doi.org\/10.1093\/hmg\/ddq340.","journal-title":"Hum Mol Genet"},{"issue":"4","key":"3552_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1002030","volume":"7","author":"SJ Grice","year":"2011","unstructured":"Grice SJ, Liu JL. Survival motor neuron protein regulates stem cell division, proliferation, and differentiation in Drosophila. PLoS Genet. 2011;7(4):e1002030. https:\/\/doi.org\/10.1371\/journal.pgen.1002030.","journal-title":"PLoS Genet"},{"issue":"8","key":"3552_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101659","volume":"5","author":"T Grass","year":"2024","unstructured":"Grass T, Dokuzluoglu Z, Buchner F, et al. Isogenic patient-derived organoids reveal early neurodevelopmental defects in spinal muscular atrophy initiation. Cell Rep Med. 2024;5(8):101659. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101659.","journal-title":"Cell Rep Med"},{"issue":"2","key":"3552_CR42","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1152\/jn.00513.2022","volume":"131","author":"VCK Cheung","year":"2024","unstructured":"Cheung VCK, Ha SCW, Zhang-Lea JH, et al. Motor patterns of patients with spinal muscular atrophy suggestive of sensory and corticospinal contributions to the development of locomotor muscle synergies. J Neurophysiol. 2024;131(2):338\u201359. https:\/\/doi.org\/10.1152\/jn.00513.2022.","journal-title":"J Neurophysiol"},{"issue":"1","key":"3552_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s11689-025-09592-x","volume":"17","author":"H Nie","year":"2025","unstructured":"Nie H, Lan S, Wang H, et al. Reduced white matter integrity and disrupted brain network in children with type 2 and 3 spinal muscular atrophy. J Neurodev Disord. 2025;17(1):3. https:\/\/doi.org\/10.1186\/s11689-025-09592-x.","journal-title":"J Neurodev Disord"},{"issue":"20","key":"3552_CR44","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.192835","volume":"10","author":"F Genovese","year":"2025","unstructured":"Genovese F, Huang YT, Motyl AA, et al. Prenatal SMN-dependent defects in translation uncover reversible primary cilia phenotypes in spinal muscular atrophy. JCI Insight. 2025;10(20):e192835. https:\/\/doi.org\/10.1172\/jci.insight.192835.","journal-title":"JCI Insight"},{"issue":"578","key":"3552_CR45","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb6871","volume":"13","author":"L Kong","year":"2021","unstructured":"Kong L, Valdivia DO, Simon CM, et al. Impaired prenatal motor axon development necessitates early therapeutic intervention in severe SMA. Sci Transl Med. 2021;13(578):eabb6871. https:\/\/doi.org\/10.1126\/scitranslmed.abb6871.","journal-title":"Sci Transl Med"},{"issue":"18","key":"3552_CR46","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1093\/hmg\/ddr275","volume":"20","author":"TT Le","year":"2011","unstructured":"Le TT, McGovern VL, Alwine IE, et al. Temporal requirement for high SMN expression in SMA mice. Hum Mol Genet. 2011;20(18):3578\u201391. https:\/\/doi.org\/10.1093\/hmg\/ddr275.","journal-title":"Hum Mol Genet"},{"issue":"17","key":"3552_CR47","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.1093\/hmg\/ddu169","volume":"23","author":"KL Robbins","year":"2014","unstructured":"Robbins KL, Glascock JJ, Osman EY, Miller MR, Lorson CL. Defining the therapeutic window in a severe animal model of spinal muscular atrophy. Hum Mol Genet. 2014;23(17):4559\u201368. https:\/\/doi.org\/10.1093\/hmg\/ddu169.","journal-title":"Hum Mol Genet"},{"issue":"3","key":"3552_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/ijns10030056","volume":"10","author":"K Cooper","year":"2024","unstructured":"Cooper K, Nalbant G, Sutton A, et al. Systematic review of presymptomatic treatment for spinal muscular atrophy. Int J Neonat Screen. 2024;10(3):56. https:\/\/doi.org\/10.3390\/ijns10030056.","journal-title":"Int J Neonat Screen"},{"issue":"1","key":"3552_CR49","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1124\/jpet.113.212407","volume":"350","author":"F Rigo","year":"2014","unstructured":"Rigo F, Chun SJ, Norris DA, et al. Pharmacology of a central nervous system delivered 2\u2019-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates. J Pharmacol Exp Ther. 2014;350(1):46\u201355. https:\/\/doi.org\/10.1124\/jpet.113.212407.","journal-title":"J Pharmacol Exp Ther"},{"issue":"18","key":"3552_CR50","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377(18):1713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1706198.","journal-title":"N Engl J Med"},{"issue":"15","key":"3552_CR51","doi-asserted-by":"publisher","first-page":"6501","DOI":"10.1021\/acs.jmedchem.8b00741","volume":"61","author":"H Ratni","year":"2018","unstructured":"Ratni H, Ebeling M, Baird J, et al. Discovery of Risdiplam, a selective survival of motor neuron-2 ( SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA). J Med Chem. 2018;61(15):6501\u201317. https:\/\/doi.org\/10.1021\/acs.jmedchem.8b00741.","journal-title":"J Med Chem"},{"issue":"1","key":"3552_CR52","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3233\/JND-230136","volume":"11","author":"H K\u00f6lbel","year":"2024","unstructured":"K\u00f6lbel H, Kopka M, Modler L, et al. Impaired neurodevelopment in children with 5q-SMA - 2 years after newborn screening. J Neuromuscul Dis. 2024;11(1):143\u201351. https:\/\/doi.org\/10.3233\/JND-230136.","journal-title":"J Neuromuscul Dis"},{"issue":"5","key":"3552_CR53","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1136\/archdischild-2023-326613","volume":"109","author":"B Buchignani","year":"2024","unstructured":"Buchignani B, Cicala G, Cumbo F, et al. Communicative Development Inventory in type 1 and presymptomatic infants with spinal muscular atrophy: a cohort study. Arch Dis Child. 2024;109(5):395\u2013401. https:\/\/doi.org\/10.1136\/archdischild-2023-326613.","journal-title":"Arch Dis Child"},{"key":"3552_CR54","doi-asserted-by":"publisher","unstructured":"Brusa C, Buchignani B, Cutri C, et al. Expressive language and social communication abilities in children with spinal muscular atrophy type 1. Dev Med Child Neurol. 2025. https:\/\/doi.org\/10.1111\/dmcn.16461.","DOI":"10.1111\/dmcn.16461"},{"key":"3552_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1326528","volume":"15","author":"I Bitetti","year":"2024","unstructured":"Bitetti I, Manna MR, Stella R, Varone A. Motor and neurocognitive profiles of children with symptomatic spinal muscular atrophy type 1 with two copies of SMN2 before and after treatment: a longitudinal observational study. Front Neurol. 2024;15:1326528. https:\/\/doi.org\/10.3389\/fneur.2024.1326528.","journal-title":"Front Neurol"},{"key":"3552_CR56","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejpn.2024.05.002","volume":"51","author":"P Steffens","year":"2024","unstructured":"Steffens P, Weiss D, Perez A, et al. Cognitive function in SMA patients with 2 or 3 SMN2 copies treated with SMN-modifying or gene addition therapy during the first year of life. Eur J Paediatr Neurol. 2024;51:17\u201323. https:\/\/doi.org\/10.1016\/j.ejpn.2024.05.002.","journal-title":"Eur J Paediatr Neurol"},{"issue":"1","key":"3552_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-12484-8","volume":"15","author":"B Buchignani","year":"2025","unstructured":"Buchignani B, Coratti G, Cutr\u00ec C, et al. Neurodevelopmental and mental disorders in children with Type I and presymptomatic Spinal Muscular Atrophy. Sci Rep. 2025;15(1):26984. https:\/\/doi.org\/10.1038\/s41598-025-12484-8.","journal-title":"Sci Rep"},{"issue":"20","key":"3552_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10204777","volume":"10","author":"R D\u2019Alessandro","year":"2021","unstructured":"D\u2019Alessandro R, Ragusa N, Vacchetti M, et al. Assessing cognitive function in neuromuscular diseases: a pilot study in a sample of children and adolescents. J Clin Med. 2021;10(20):4777. https:\/\/doi.org\/10.3390\/jcm10204777.","journal-title":"J Clin Med"},{"issue":"10","key":"3552_CR59","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.nmd.2023.08.005","volume":"33","author":"B Buchignani","year":"2023","unstructured":"Buchignani B, Cicala G, Moriconi F, et al. Profile of cognitive abilities in spinal muscular atrophy type II and III: what is the role of motor impairment? Neuromuscul Disord. 2023;33(10):711\u20137. https:\/\/doi.org\/10.1016\/j.nmd.2023.08.005.","journal-title":"Neuromuscul Disord"},{"issue":"11","key":"3552_CR60","doi-asserted-by":"publisher","first-page":"3736","DOI":"10.1016\/j.ridd.2013.07.027","volume":"34","author":"L Visser","year":"2013","unstructured":"Visser L, Ruiter SAJ, Van der Meulen BF, Ruijssenaars WAJJM, Timmerman ME. Validity and suitability of the Bayley-III Low Motor\/Vision version: a comparative study among young children with and without motor and\/or visual impairments. Res Dev Disabil. 2013;34(11):3736\u201345. https:\/\/doi.org\/10.1016\/j.ridd.2013.07.027.","journal-title":"Res Dev Disabil"},{"issue":"1","key":"3552_CR61","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/PEP.0000000000000004","volume":"26","author":"L Visser","year":"2014","unstructured":"Visser L, Ruiter SAJ, van der Meulen BF, Ruijssenaars WAJJM, Timmerman ME. Accommodating the Bayley-III for motor and\/or visual impairment: a comparative pilot study. Pediatr Phys Ther. 2014;26(1):57\u201367. https:\/\/doi.org\/10.1097\/PEP.0000000000000004.","journal-title":"Pediatr Phys Ther"},{"issue":"4","key":"3552_CR62","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3233\/JND-221627","volume":"10","author":"A Wennberg","year":"2023","unstructured":"Wennberg A, Lenzoni S, Turcano P, et al. Subjective sleep quality as it relates to cognitive and physical function in Spinal Muscular Atrophy patients. J Neuromuscul Dis. 2023;10(4):713\u20137. https:\/\/doi.org\/10.3233\/JND-221627.","journal-title":"J Neuromuscul Dis"},{"issue":"8","key":"3552_CR63","doi-asserted-by":"publisher","first-page":"6307","DOI":"10.1007\/s12035-017-0831-9","volume":"55","author":"A Govoni","year":"2018","unstructured":"Govoni A, Gagliardi D, Comi GP, Corti S. Time is motor neuron: therapeutic window and its correlation with pathogenetic mechanisms in Spinal Muscular Atrophy. Mol Neurobiol. 2018;55(8):6307\u201318. https:\/\/doi.org\/10.1007\/s12035-017-0831-9.","journal-title":"Mol Neurobiol"},{"issue":"5","key":"3552_CR64","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000200193","volume":"10","author":"E Groulx-Boivin","year":"2024","unstructured":"Groulx-Boivin E, Oliveira-Carneiro A, Carlson H, et al. Macrostructural brain abnormalities in spinal muscular atrophy: a case-control study. Neurol Genet. 2024;10(5):e200193. https:\/\/doi.org\/10.1212\/NXG.0000000000200193.","journal-title":"Neurol Genet"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03552-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03552-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03552-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:11:11Z","timestamp":1785517871000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03552-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":64,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["3552"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03552-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"7 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Kentaro Okamoto has received honoraria for invited lectures from Biogen Japan (2021) and Chugai Pharmaceutical Co., Ltd. (a member of the Roche Group) (2022). The author declares no other conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by the author.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}